COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION AMONG INFANTS IN RUSSIA- ECONOMIC EVALUATION OF THE PNEUMOCOCCAL 7-VALENT CONJUGATE VACCINE

Author(s)

Omelyanovsky VV1, Krysanov I2, Ivakhnenko O21Institute of Clinico-Economic Expertise and Pharmacoeconomics, RSMU, Moscow, Russia, 2Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Moscow, Russia

OBJECTIVES: Cost-effectiveness analysis of 4 dose (3+1) schedule of the conjugate pneumococcal 7-valent vaccine (PCV-7) in infants in the Russian Federation. METHODS: Costs associated with  Streptococcus pneumoniae  infection were calculated in a modeled cohort of children 0-5 years old with and without vaccination with PCV-7. Key parameters in the model included: number of children in the age of 0-5 years in the country; incidence of diseases caused by S. pneumoniae; the data about efficacy of PVC-7. Costs of vaccination, medical care costs and economic losses of a society were taken into account from the societal point of view. Time horizon was 5 years in the model. RESULTS: Expected cost of  vaccination program is €0.469 million. Implementation of vaccination with PCV-7 will decrease direct medical costs of care for S. pneumoniae  infection by €0.516 million. Societal economic losses will decrease by €0.975 million. Thus  benefit amount of the PCV-7 vaccination program in a cohort of 0-5 years old children will be €1022 million. CONCLUSIONS: Vaccination with PCV-7 is an efficient program in Russia.

Conference/Value in Health Info

2010-11, ISPOR Europe 2010, Prague, Czech Republic

Value in Health, Vol. 13, No. 7 (November 2010)

Code

PIN40

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Infectious Disease (non-vaccine), Vaccines

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×